Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1987-8-7
|
| pubmed:abstractText |
The antimetabolite 5-fluorouracil (5-FU) was used as adjunctive treatment in glaucomatous eyes with poor prognoses undergoing filtering surgery. By adjusting the frequency of postoperative 5-FU subconjunctival injections according to the clinical response, the author thought it might be possible to reduce episcleral fibroproliferation and maintain a patent filter while reducing complications. Sixty-three eyes underwent filtering surgery with subsequent subconjunctival injections of 5.0 to 7.5 mg 5-FU for 14 days. The antimetabolite was not administered if there was evidence of corneal toxicity as demonstrated by epithelial defects or filaments, flat anterior chamber, or a conjunctival wound leak. By adjusting the injections in this fashion, the total amount of 5-FU administered ranged between 17.5 and 62.5 mg (34.4 +/- 11.6 mg). After 1 year, successful surgical outcomes were observed in 13/15 eyes with aphakia (87%), 11/17 eyes with neovascular glaucoma (65%), 11/12 eyes with at least two previous failed filters (92%), and 5/6 eyes with inflammatory glaucoma (83%). Eyes with epithelial downgrowth and cicatrizing diseases of the conjunctiva also were treated. Overall, conjunctival wound leaks were observed in 24% of the eyes and 29% had detectable changes in their corneal epithelium with corneal defects and filaments. Although adjusting the dose of 5-FU appears to be safe and effective, this can be determined clearly only by a controlled randomized clinical trial.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0161-6420
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
564-70
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2439972-Adult,
pubmed-meshheading:2439972-Aged,
pubmed-meshheading:2439972-Female,
pubmed-meshheading:2439972-Fluorouracil,
pubmed-meshheading:2439972-Glaucoma,
pubmed-meshheading:2439972-Humans,
pubmed-meshheading:2439972-Inflammation,
pubmed-meshheading:2439972-Intraocular Pressure,
pubmed-meshheading:2439972-Iris,
pubmed-meshheading:2439972-Male,
pubmed-meshheading:2439972-Methods,
pubmed-meshheading:2439972-Middle Aged,
pubmed-meshheading:2439972-Neovascularization, Pathologic,
pubmed-meshheading:2439972-Postoperative Care,
pubmed-meshheading:2439972-Postoperative Complications,
pubmed-meshheading:2439972-Trabecular Meshwork,
pubmed-meshheading:2439972-Visual Acuity
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects.
|
| pubmed:publicationType |
Journal Article
|